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Available online xxxxSchizophrenia is a chronic psychiatric disorderwith complex genetic and environmental origins.Whilemany an-
tipsychotics have been demonstrated as effective in the treatment of schizophrenia, a substantial number of
schizophrenia patients are partially or fully unresponsive to the treatment. Clozapine is the most effective anti-
psychotic drug for treatment-resistant schizophrenia; however, clozapine has rare but serious side-effects. Fur-
thermore, there is inter-individual variability in the drug response to clozapine treatment. Therefore, the
identiﬁcation of the molecular mechanisms underlying the action of clozapine and drug response predictors is
imperative. In the present study,we focused on a pair ofmonozygotic twin caseswith treatment-resistant schizo-
phrenia, inwhich one twin respondedwell to clozapine treatment and the other twin did not. Using induced plu-
ripotent stem (iPS) cell-based technology, we generated neurons from iPS cells derived from these patients and
subsequently performed RNA-sequencing to compare the transcriptome proﬁles of themock or clozapine-treat-
edneurons. Although, these iPS cells similarly differentiated into neurons, several genes encoding homophilic cell
adhesion molecules, such as protocadherin genes, showed differential expression patterns between these two
patients. These results, which contribute to the current understanding of themolecular mechanisms of clozapine
action, establish a new strategy for the use of monozygotic twin studies in schizophrenia research.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Schizophrenia is a severe neuropsychiatric disease with an approxi-
mate worldwide prevalence of 1% (Gaebel and Zielasek, 2015; Millan et
al., 2016;Wang et al., 2015). Common symptoms include delusions, hal-
lucinations, impaired cognitive function, emotional blunting and inco-
herent behavior. Although many typical and atypical antipsychotic
drugs have been developed and demonstrated to be effective in the
treatment of schizophrenia, 20–30% of patients remain partially or
fully unresponsive to two or more adequate trials with antipsychotic
drugs and are therefore classiﬁed as treatment resistant (Kane et al.,
1988; Meltzer, 1997, 2013). Patients with treatment-resistant schizo-
phrenia suffer disability andhave a poor quality of life. Despite the social
and economic burden of treatment resistance, the molecular patho-
physiology of treatment-resistant schizophrenia remains poorly
understood.
Clozapine is the only effective drug for treatment-resistant schizo-
phrenia (Hill and Freudenreich, 2013; Meltzer, 2013; Raja and Raja,
2014). At six months, the response rate to clozapine in treatment-resis-
tant schizophrenia patients is 60–70%. Although the efﬁcacy of cloza-
pine for treatment-resistant schizophrenia is remarkable, clozapine
has life-threatening side effects, such as agranulocytosis, which requires
medical monitoring. These factors limit the use of this compound in
clinical practice. To maximize the efﬁcacy and minimize the side effects
of clozapine treatment, biologically validated predictors of the clozapine
treatment response should be identiﬁed. However, considering that
inter-individual variability in the drug efﬁcacy of clozapine treatment
exists and that the molecular mechanisms of clozapine action remain
largely unclear, the current molecular knowledge of drug response pre-
dictors of clozapine is extremely limited (Gressier et al., 2016;
Kohlrausch, 2013; Muller et al., 2013; Sriretnakumar et al., 2015).
Considering the very limited accessibility to live neurons from pa-
tients with schizophrenia, the molecular defects in neurons leading to
the initiation and progression of this disease remain obscure. Accord-
ingly, schizophrenia is poorly understood at the molecular and cellular
levels. Modeling schizophrenia using induced pluripotent stem (iPS)
cells offers an emerging opportunity to examine the mechanisms un-
derlying complex disease pathogenesis (Falk et al., 2016; Imaizumi
and Okano, 2014; Okano and Yamanaka, 2014;Wright et al., 2014). Par-
ticularly, iPS cell technologies can produce live human neuronswith the
genetic backgrounds that lead to schizophrenia (Bundo et al., 2014;
Hashimoto-Torii et al., 2014; Maekawa et al., 2015; Robicsek et al.,
2013; Topol et al., 2016;Wen et al., 2014; Yoon et al., 2014). Considering
the high heritability of schizophrenia, schizophrenia patient-derived
live neurons with the same genetic information as the patient can be
ideal experimental materials for studies of the molecular pathophysiol-
ogy of schizophrenia.
Monozygotic twins have been useful resources for studying the ge-
netic and environmental factors of schizophrenia (Boomsma et al.,
2002; Kato et al., 2005). Molecular biological methods using blood sam-
ples and brain imaging methods have been conventionally used in dis-
cordant monozygotic twins to investigate the potential mechanisms of
schizophrenia. Currently, to the best of our knowledge, there are no re-
ports on the use of iPS cell technology in monozygotic twin studies of
schizophrenia. In the present study, to elucidate the molecular mecha-
nism of inter-individual variability in the clozapine response and cloza-
pine action, we focused on monozygotic twin cases with treatment-
resistant schizophrenia who were discordant for clozapine treatment,
i.e., one twin responded well to clozapine treatment and the other
twin did not. We established iPS cells from immortalized B cells of
each patient and neurons were differentiated from these iPS cells. We
subsequently performedRNA sequencing to compare the transcriptome
proﬁles of the mock or clozapine-treated neurons as well as
lymphoblastoid B-cell lines from these patients and observed that sev-
eral genes, including cell adhesion molecules, showed differential ex-
pression patterns between these two patients.Please cite this article as: Nakazawa, T., et al., Differential gene expression
iPS cells from monozygotic twin..., Schizophr. Res. (2016), http://dx.doi.or2. Materials and methods
Following a description of the study, written informed consent was
obtained from each subject. This study was conducted in accordance
with the World Medical Association's Declaration of Helsinki and ap-
proved through the Research Ethics Committee of Osaka University.
All recombinant DNA experiments were reviewed and approved by
the Gene Modiﬁcation Experiments Safety Committee of Osaka
University.
2.1. Subjects
The monozygotic twin patients with treatment-resistant schizo-
phrenia were recruited at Osaka University Hospital. Each subject was
diagnosed and assessed by at least two trained psychiatrists according
to the Diagnostic and Statistical Manual of Mental Disorders, fourth edi-
tion (DSM-IV) criteria based on a structured clinical interview. Treat-
ment-resistant schizophrenia was deﬁned according to the following
criteria mentioned in the clozapine drug information in Japan: 1) No
or little response to treatment from at least two adequately dosed anti-
psychotic trials for at least 4 weeks (including at least 1 second-genera-
tion antipsychotic, N600 mg/day of chlorpromazine equivalent) and
Global Assessment of Functioning (GAF) scores never higher than 41;
or 2) intolerance to at least two second-generation antipsychotics due
to extrapyramidal symptoms. The subjects included in the present
study met the criterion of little response. Symptoms of schizophrenia
were assessed using the Positive and Negative Syndrome Scale
(PANSS). Written informed consent was obtained from subjects after
the procedures were fully explained.
2.1.1. Clozapine-responder (CLZ-responder)
Thepatientwas a 59-year-old Japanese female diagnosedwith treat-
ment-resistant schizophrenia whose symptoms were improved after
clozapine treatment. The PANSS andGAF scores prior to clozapine treat-
ment were PANSS positive, 19; negative, 25; general, 44; and GAF, 23.
After clozapine treatment, the PANSS and GAF scores were PANSS pos-
itive, 14; negative, 19; general, 40; and GAF, 33. Prior to clozapine treat-
ment, the patient could not leave her house and could not perform
housework due to delusions. However, after clozapine treatment, the
patient could leave the house and perform housework, reﬂecting the
improvement of positive and negative symptoms.
2.1.2. Clozapine-non-responder (CLZ-non-responder)
Thepatientwas a 59-year-old Japanese female diagnosedwith treat-
ment-resistant schizophrenia whose symptoms were not improved
after clozapine treatment. The PANSS and GAF scores prior to clozapine
treatment were PANSS positive, 29; negative, 20; general, 48; and GAF,
23. After clozapine treatment, the PANSS and GAF scores were PANSS
positive, 26; negative, 23; general, 51; andGAF, 21. The patientwas con-
stantly affected by delusions concerning God before and after clozapine
treatment.
2.2. Generation of iPS cells
The generation of iPS cells from lymphoblastoid B-cell lines was per-
formed as previously described (Fujimori et al., 2016). The isolation of
lymphocytes from patient blood samples and the immortalization of
these cells using Epstein-Barr virus were performed by Special Refer-
ence Laboratories, Inc. (Tokyo, Japan) (Yamamori et al., 2011). Immor-
talized lymphoblastoid B-cell lines obtained from the schizophrenia
monozygotic twin were grown in Roswell Park Memorial Institute
(RPMI) medium supplemented with 20% fetal bovine serum. The im-
mortalized lymphoblastoid B-cell lines (2 × 106 cells) were
electroporated with 0.63 μg of pCE-hOCT3/4, 0.63 μg of pCE-hSK,
0.63 μg of pCE-hUL, 0.63 μg of pCE-mp53DD and 0.50 μg of pCXB-
EBNA1 (Addgene, MA, USA) using the Nucleofector 2b Device (Lonza,proﬁles in neurons generated from lymphoblastoid B-cell line-derived
g/10.1016/j.schres.2016.10.012
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(Lonza) (Program, U-008). After electroporation, the immortalized
lymphoblastoid B-cell lines were grown in RPMI medium supplement-
ed with 10% fetal bovine serum for 1 week. Subsequently, the
electroporated cells were seeded onto mitomycin C-treated mouse
SNL feeder cells and maintained for 20–30 days in standard human ES
cell medium consisting of Dulbecco's modiﬁed Eagle's medium
(DMEM)/F12 medium supplemented with 20% KnockOut serum re-
placement (Thermo Fisher Scientiﬁc, MA, USA), 1% of Non-essential
Amino Acid Solution (NEAA) (Sigma-Aldrich, MO, USA), 2 mM of L-glu-
tamine (Thermo Fisher Scientiﬁc), 0.1 mM of 2-mercaptoethanol
(Wako Chemicals, Tokyo, Japan) and 4 ng/ml of bFGF (Peprotech, NJ,
USA). Subsequently, the colonies similar to human ES cellswere clonally
isolated, morphologically selected, subjected to a PCR-based analysis of
episomal vector loss and evaluated for the expression of pluripotent
markers using immunohistochemistry (Oct-4A, Sox2, TRA-1-60 and
TRA-1-81). Antibodies against Oct-4A, Sox2, TRA-1-60 and TRA-1-81
were purchased from Cell Signaling (MA, USA).
2.3. In vitro differentiation of iPS cells into excitatory neurons
For in vitro differentiation, iPS cells were transferred under feeder-
free conditions ontoMatrigel (Corning, NY, USA)-coated dishes and cul-
tured in the chemically deﬁned Essential 8 medium (Thermo Fisher Sci-
entiﬁc) according to the manufacturer's instructions. The in vitro
differentiation of iPS cells into neurons through Neurogenin2 (Ngn2)
overexpression was performed according to Zhang et al. (Zhang et al.,
2013), with minor modiﬁcations. On day 0, iPS cells were infected
with recombinant lentiviruses expressing the reverse tetracycline
transactivator (#20342 (Addgene)) and Neurogenin2-T2A-Puro under
the TetO enhancer upstream of the minimal CMV promoter (#20321
and #34999 (Addgene); QM200PA-1 (System Biosciences, CA, USA))
in Essential 8 Medium containing 10 μMof Y-27632 (Wako Chemicals).
On day 1, the culture medium was replaced with DMEM/F12/N2 con-
taining 1% NEAA (Thermo Fisher Scientiﬁc), 10 μM of Y-27632,
10 ng/ml of human BDNF (R&D Systems, MN, USA), 10 ng/ml of
human NT3 (R&D Systems), 200 ng/ml of mouse laminin (Thermo Fish-
er Scientiﬁc) and 2 μg/ml of human ﬁbronectin (Thermo Fisher Scientif-
ic). Doxycycline (Clontech, CA, USA) (2 μg/ml) was added on day 1 to
induce TetO gene expression. On day 2, the culture medium was re-
placed with the DMEM/F12/N2medium containing 1 μg/ml of puromy-
cin (Wako Chemicals). On day 3, the culturemediumwas replacedwith
Neurobasal medium (Thermo Fisher Scientiﬁc) supplemented with B-
27 (Thermo Fisher Scientiﬁc), 1% Glutamax (Thermo Fisher Scientiﬁc),
10 μM of Y-27632, 10 ng/ml of human BDNF, 10 ng/ml of human NT3,
200 ng/ml of mouse laminin, 2 μg/ml of human ﬁbronectin and 2 μg/
ml of doxycycline. After day 3, 50% of the medium was exchanged
every 2 days. On day 8, 10 μMof Ara-C (Sigma-Aldrich) and 1 μMof clo-
zapine (Sigma-Aldrich) (or mock) were added to the medium. On day
15, Ngn2-induced neurons were stained with a neuron marker, class
III β-tubulin (Tuj1, Biolegend, CA, USA) or were harvested to isolate
total RNA for RNA sequencing. Neuronal nuclei were stained with
Hoechst 33258 (Calbiochem, CA, USA).
2.4. Immunocytochemistry
Immunocytochemistry of iPS cells and differentiated neurons was
performed as previously described (Nakazawa et al., 2016).
2.5. RNA sequence
Total RNA from lymphoblastoid B-cell lines (P0052 and P0070) and
iPS cell-derived differentiated neurons (P0052-1B, -2B, -4B, P0070-2B,
-6B and -9B) was isolated using the PureLink RNA Micro Kit (Thermo
Fisher Scientiﬁc) according to the manufacturer's instructions. Equal
amounts of total RNAs from each patient were combined (for iPS cell-Please cite this article as: Nakazawa, T., et al., Differential gene expression
iPS cells from monozygotic twin..., Schizophr. Res. (2016), http://dx.doi.orderived differentiated neurons) and sequenced using the Illumina
HiSeq2000 system (BGI, Beijing, China). The generated fastq ﬁles were
subjected to quality control. Subsequently, the reads were aligned to
the human reference genome hg19 and the reference genes using
BWA and Bowtie software (BGI, Beijing, China), respectively. The
aligned reads were processed using RSEM (Li and Dewey, 2011). The
gene expression levelsweremeasured based on Fragments Per Kilobase
of exon perMillionmapped (FPKM).We compared the gene expression
levels between the clozapine- and mock-treated neurons and
lymphoblastoid B-cell lines of each patient to identify clozapine respon-
sive genes. We also compared the gene expression levels of the mock-
treated neurons and lymphoblastoid B-cell lines to identify differential-
ly expressed genes between each patient in the basal state. We per-
formed differential gene expression analysis based on a Poisson
distribution to identify differentially expressed genes (BGI, Beijing,
China). The false discovery rate (FDR) was used to correct for multiple
testing. The signiﬁcance level was set at FDR b 0.05. The Z-scorewas cal-
culated as (xi,j − μi) / σi, where xi,j is the expression level of gene i in
sample j, and μi andσi are the average expression level and standard de-
viation, respectively, of gene i across samples. We calculated Fisher's
exact p values for the identiﬁcation of genes showing differential ex-
pression patterns in the same direction between the iPS-derived neu-
rons and lymphoblastoid B-cell lines.
2.6. Gene ontology and pathway analysis
We used the Database for Annotation, Visualization and Integrated
Discovery (DAVID) to perform Gene Ontology (GO)-based functional
classiﬁcation of differentially expressed genes. Fisher's exact p values
were calculated to search for overlapped GO terms. The calculated p
values were adjusted using FDR to correct for multiple testing. The sig-
niﬁcance level was set at FDR b 0.05.
3. Results
3.1. Generation of iPS cells from a pair of monozygotic twins with treat-
ment-resistant schizophrenia
Weused a non-integrating approachwith episomal vectors express-
ing OCT3/4, SOX2, KLF4, L-MYC, LIN28, dominant negative TP53 and
EBNA1 to establish iPS cell lines using the immortalized B cells obtained
from monozygotic twin patients with treatment-resistant schizophre-
nia and discordant clozapine responses, i.e., one twin responded well
to clozapine treatment (patient number, P0070, hereafter clozapine
(CLZ)-responder) and the other twin did not (patient number, P0052,
hereafter CLZ-non-responder) (see Materials and Methods for patient
information). Each iPS cell line was clonally isolated, morphologically
selected, subjected to PCR-based analysis of episomal vector loss and
evaluated for the expression of pluripotent markers (Oct-4A, Sox2,
TRA-1-60 and TRA-1-81) (Fig. 1). Based on these criteria, we selected
three clones from the CLZ-non-responder (P0052-1B, -2B and -4B)
and three clones from CLZ-responder (P0070-2B, -6B and -9B) for fur-
ther analysis.
3.2. Clozapine responsive genes in iPS cell-derived differentiated neurons
Using the forced expression of the neuronal transcription factor
Ngn2 (Zhang et al., 2013), we generated differentiated neurons from
each iPS cell clone obtained from the CLZ-non-responder and CLZ-re-
sponder (Fig. 1, right). To identify differentially expressed genes in re-
sponse to clozapine treatment in each patient, we conducted RNA-seq
and compared the global gene expression data obtained for the differen-
tiated neurons treated with mock or 1 μM of clozapine for 1 week. For
the RNA-seq experiments, total RNA (P0052-1B, -2B, -4B, P0070-2B,
-6B and -9B) was isolated from each clone and equal amounts of total
RNAs from each patient were combined and sequenced using theproﬁles in neurons generated from lymphoblastoid B-cell line-derived
g/10.1016/j.schres.2016.10.012
BrightfieldOct4Sox2TRA-1-60TRA-1-81
NeuroniPS cells
Tuj1/ Hoechst
100 µm
CLZ-non-responder
CLZ-responder
Fig. 1. Representative images of iPS cells and Ngn2-induced neurons from the CLZ-non-responder and CLZ-responder. iPS cells were stained for pluripotencymarkers (Oct4, Sox2, TRA-1-
60 and TRA-1-81). Ngn2-induced neurons were stained with a neuron marker, Tuj1 (green). Neuronal nuclei were stained with Hoechst 33258 (blue). Scale bar, 100 μm.
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of 22 and 46 genes were upregulated and downregulated, respectively,
in the mixed sample from the differentiated neurons from the CLZ-re-
sponder (|FC| N 1, FDR b 0.05) (Table 1 and Supplementary Table 1).
Likewise, a total of 28 and 24 geneswere upregulated and downregulat-
ed, respectively, in the mixed sample from the differentiated neurons
from the CLZ-non-responder (|FC| N 1, FDR b 0.05) (Table 1 and Supple-
mentary Table 2). Among the 68 genes that were clozapine-responsive
in the CLZ-responder, 20 and 44 genes were uniquely upregulated and
downregulated, respectively, in the CLZ-responder but not in the CLZ-
non-responder (Table 1 andSupplementary Table 3). ADatabase for An-
notation, Visualization and IntegratedDiscovery (DAVID) analysis of the
64 genes that were uniquely upregulated or downregulated in the
CLZ-responder showed that these genes were modestly enriched
in the GO annotations for cell adhesion/biological adhesion (TNR,
PCDHA13, PCDHGA4, PCDHGC5, GP1BB and ITGA9) and homophilic
cell adhesion (PCDHA13, PCDHGA4 and PCDHGC5) (Table 2); howev-
er, the enrichment of these GO annotations was not statistically sig-
niﬁcant (FDR N 0.05). We next conducted RNA-seq and compared
the global gene expression data obtained for the patients' lymphoblastoid
B-cell lines treatedwithmockor 1 μMof clozapine for 1week. In response
to clozapine treatment, a total of 22 and 38 genes were upregulated and
downregulated, respectively, in the sample from the lymphoblastoid B-
cell lines from the CLZ-responder (|FC| N 1, FDR b 0.05) (data not
shown). Likewise, a total of 38 and 61 geneswere upregulated and down-
regulated, respectively, in the sample from the lymphoblastoid B-cell
lines from the CLZ-non-responder (|FC| N 1, FDR b 0.05) (data not
shown). We then focused uniquely upregulated or downregulated
genes in the iPS cell-derived neurons fromCLZ-responder thatweremod-
estly enriched in the GO annotations for cell adhesion/biological adhesion
and homophilic cell adhesion (cell adhesion/biological adhesion, TNR,
PCDHA13, PCDHGA4, PCDHGC5, GP1BB and ITGA9; homophilic cell adhe-
sion, PCDHA13, PCDHGA4 and PCDHGC5) (|FC| N 1, FDR b 0.05) (TableTable 1
The number of clozapine-responsive genes in the CLZ-non-responder and CLZ-responder.
Upregulated Downregulated
CLZ-responder 22 46
CLZ-non-responder 28 24
CLZ-responder-speciﬁc 20 44
Please cite this article as: Nakazawa, T., et al., Differential gene expression
iPS cells from monozygotic twin..., Schizophr. Res. (2016), http://dx.doi.or2). We found that none of these genes showed a differential expression
pattern in the same direction upon clozapine treatment between the iPS
cell-derived neurons and lymphoblastoid B-cell lines from the CLZ-re-
sponder (Supplementary Table 4), suggesting that their lymphoblastoid
B-cell lineage may not contribute to the differential gene expression pat-
terns in the iPS cell-derived neurons between the patients (FDR N 0.05).3.3. Gene expression analysis in iPS cell-derived differentiated neurons in
the basal state
Monozygotic twins are derived from the same single cell and there-
fore share their genetic variations (Boomsma et al., 2002). As expected,
exome sequencing did not reveal differences in the DNA sequence be-
tween the twins (data not shown). Nevertheless, monozygotic twins
generally show discordant global gene expression proﬁles, potentially
leading to phenotypic discordance (Boomsma et al., 2002; Kato et al.,
2005). Therefore, we compared the global gene expression data obtain-
ed for the mock-treated differentiated neurons. We observed that the
expression levels of a total of 167 genes were higher in the CLZ-re-
sponder compared with those in the CLZ-non-responder (|FC| N 1,
FDR b 0.05) (Supplementary Table 5). Similarly, the expression levels
of a total of 95 genes were lower in the CLZ-responder compared with
those in the CLZ-non-responder (|FC| N 1, FDR b 0.05) (Supplementary
Table 6). DAVID analysis of the 262 genes revealed an enriched func-
tional group in homophilic cell adhesion (FDR = 4.76 × 10−4) (higher,
PCDHGB3, CDH8, PCDHB15, PCDHGB1, PCDHGA11, PCDHGA6 and DSC3;
lower, PCDHGC3, PCDHA7, PCDHGA7 and PCDHA13) (Table 3 and
Fig. 2). We also observed that these genes were modestly enriched in
the GO annotations for cell adhesion/biological adhesion (PCDHA7,
PCDHGA11, CNTNAP5, TNC, PCDHB15, PCDHGA7, PCDHGA6, FER,
PCDHGC3, PCDHGB3, CDH8, ITGA9, PCDHGB1, GP1BB, TNR, DSC3, RELN,Table 2
Top GO annotations for speciﬁcally upregulated or downregulated genes in the clozapine-
treated CLZ-responder.
Annotations No. of genes p value
GO:0007155 cell adhesion 6 5.65E-03
GO:0022610 biological adhesion 6 5.68E-03
GO:00007156 homophilic cell adhesion 3 2.06E-02
proﬁles in neurons generated from lymphoblastoid B-cell line-derived
g/10.1016/j.schres.2016.10.012
Table 3
Differentially expressed genes annotated as being involved in homophilic cell adhesion
(GO:0007156) between the CLZ-non-responder and CLZ-responder in the basal state.
Symbol P0070 (FPKM) P0052 (FPKM) Fold changes
PCDHGB3 0.35 0.05 7.00
CDH8 4.48 0.96 4.66
PCDHB15 24.7 7.81 3.16
PCDHGB1 0.97 0.44 2.20
PCDHGA11 2.55 1.18 2.16
PCDHGA6 4.17 1.94 2.15
DSC3 0.76 0.38 2.00
PCDHGC3 36.6 75.5 0.48
PCDHA7 0.73 1.53 0.47
PCDHGA7 0.30 1.97 0.15
PCDHA13 0.11 0.82 0.13
|FC| N 1, FDR b 0.05.
Table 4
Top GO annotations for differentially expressed genes between the CLZ-responder and
CLZ-non-responder in the basal state.
Annotations Gene number p value FDR q value
GO:0007156 homophilic cell adhesion 11 3.05E-07 4.76E-04
GO:0007155 cell adhesion 19 6.02E-05 0.093
GO:0022610 biological adhesion 19 6.13E-05 0.095
GO:0045449 regulation of transcription 43 6.32E-05 0.098
5T. Nakazawa et al. / Schizophrenia Research xxx (2016) xxx–xxxPCDHA13 and ENG) and regulation of transcription (ONECUT1, TBX20,
SOX5, SOX7,WTIP, ZBTB37, GTF2H2C, LHX4, ZSCAN23, DMRTC1/1B, PER3,
SIM2, HSFX1/2, GMEB1, OTX2, IGF2, ZFP3, NPAS4, SIGIRR, MAFIP, IGSF1,
VEGFA, ZFPM2, NEUROD4, ENG, TMEM189-UBE2V1, INS-IGF2 and 17 ZNF
genes); however, the enrichment of these GO annotations was not sta-
tistically signiﬁcant (cell adhesion, FDR = 0.094; biological adhesion,
FDR = 0.096; regulation of transcription, FDR = 0.099) (Table 4). We
next conducted RNA-seq and compared the global gene expression
data obtained for the mock-treated patients' lymphoblastoid B-cell
lines. We observed that the expression levels of a total of 1170 genes
were higher in the CLZ-responder compared with those in the CLZ-
non-responder (|FC| N 1, FDR b 0.05) (data not shown). Similarly, the
expression levels of a total of 754 genes were lower in the CLZ--1.5
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Fig. 2. Differentially expressed genes annotated as being involved in homophilic cell adhesio
(upper) Higher expressed genes in the CLZ-responder. (lower) Lower expressed genes in the C
Please cite this article as: Nakazawa, T., et al., Differential gene expression
iPS cells from monozygotic twin..., Schizophr. Res. (2016), http://dx.doi.orresponder compared with those in the CLZ-non-responder (|FC| N 1,
FDR b 0.05) (data not shown). We then focused upregulated or down-
regulated genes in the iPS cell-derived neurons from the CLZ-responder
that were enriched in the GO annotation for homophilic cell adhesion
(|FC| N 1, FDR b 0.05) (Table 3). We found that DSC3, but not other
genes, showed a differential expression pattern in the same direction
between the iPS cell-derived neurons and lymphoblastoid B-cell
lines from the CLZ-responder, which is not statistically signiﬁcant
(FDR N 0.05) (Table 5 and Supplementary Table 7). We also found that
several differentially expressed genes enriched in the GO annotation
for cell adhesion/biological adhesion and regulation of transcription
showed differential expression patterns in the same direction between
the iPS cell-derived neurons and lymphoblastoid B-cell lines from the
CLZ-responder, which is not statistically signiﬁcant (FDR N 0.05) (Sup-
plementary Table 7). These results suggest that their lymphoblastoid
B-cell lineage may generally not contribute to the differential gene ex-
pression patterns in the iPS cell-derived neurons between the patients.
The information of differentially expressed genes in the lymphoblastoid
B-cell lines may be useful for eliminating noise from the gene expres-
sion patterns in the iPS cell-derived neurons.PCDHGC3
PCDHGA7
PCDHA7
PCDHA13
PCDHB15
PCDHGA6
PCDHGA11
CDH8
PCDHGB1
DSC3
PCDHGB3
LZ-non-responder
e CLZ-responder
he CLZ-responder
CLZ-non-responder
n (GO:0007156) between the CLZ-non-responder and CLZ-responder in the basal state.
LZ-responder. The expression level of each gene is expressed as a Z-score.
proﬁles in neurons generated from lymphoblastoid B-cell line-derived
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Table 5
Comparison of differential expression of genes enriched in theGO annotation for homophilic cell adhesion between lymphoblastoid B-cell lines and iPS cell-derived differentiatedneurons.
Symbol P0070 (FPKM)
(neuron)
P0052 (FPKM)
(neuron)
Fold changes
(neuron)
P0070 (FPKM)
(B cell)
P0052 (FPKM)
(B cell)
Fold changes
(B cell)
FDR q value
(B cell)
PCDHGB3 0.35 0.05 7.00 1.06 0.48 2.21 0.090
CDH8 4.48 0.96 4.66 ND ND
PCDHB15 24.7 7.81 3.16 0.12 0.001 120 0.27
PCDHGB1 0.97 0.44 2.20 0.1 0.2 0.5 0.61
PCDHGA11 2.55 1.18 2.16 0.41 0.96 0.43 0.023
PCDHGA6 4.17 1.94 2.15 0.89 0.45 1.98 0.24
DSC3 0.76 0.38 2.00 0.99 0.42 2.36 4.7E-04
PCDHGC3 36.6 75.5 0.48 6.04 3.99 1.51 3.7E-05
PCDHA7 0.73 1.53 0.47 0.11 0.18 0.61 0.76
PCDHGA7 0.30 1.97 0.15 0.49 0.09 5.44 0.074
PCDHA13 0.11 0.82 0.13 0.001 0.05 0.02 0.66
ND, not detected.
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Themolecular identiﬁcation of drug response predictors of clozapine
is directly linked to the development of new, effective treatment
strategies. However, clozapine has complex effects on various neu-
rotransmitter receptors, such as dopamine, serotonin, adrenaline,
acetylcholine and histamine receptors, preventing the understand-
ing of the molecular mechanisms of clozapine action and the identi-
ﬁcation of drug response predictors. In the present study, we
applied iPS-cell-based technology in a monozygotic twin study and
observed that several proteins involved in homophilic cell adhesion
are differentially expressed between the patients. To the best of our
knowledge, there are no reports on the use of iPS cell technology in
monozygotic twin studies of schizophrenia; however, the present
study is necessarily preliminary due to the observational nature
and its being conducted with a single pair of patients.
It is generally impossible to obtain live neurons from schizophrenia
patients. Accordingly, imaging studies of patient brains, genetic studies
of patient lymphocytes and postmortem studies of patient brains have
primarily been used in schizophrenia research (Falk et al., 2016).
While these studies signiﬁcantly contribute to the current understand-
ing of schizophrenia, the precise molecular pathogenesis of schizophre-
nia remains unclear. Because schizophrenia is a genetically complex
disorder, it is important to use live patient-derived neuronswith genetic
backgrounds of the disorder to identify the neuronal defects associated
with schizophrenia. The present and several previous studies have re-
ported the establishment of disease-speciﬁc iPS cells from patients
with schizophrenia and identiﬁed some of the pathogenic mechanisms
of schizophrenia (Brennand et al., 2011; Bundo et al., 2014; Falk et al.,
2016; Hook et al., 2014; Imaizumi and Okano, 2014; Okano and
Yamanaka, 2014; Wen et al., 2014; Wright et al., 2014). Among these
studies, the present study is unique because we used samples from
monozygotic twins with treatment-resistant schizophrenia. Impor-
tantly, one twin responded well to clozapine treatment and the
other twin did not. Because monozygotic twins share almost all of
their genetic variants, the iPS cell-derived neurons established in
the present study may be ideal experimental materials to dissect
the molecular mechanisms underlying the inter-individual variability
in the clozapine response.
Using iPS cell-derived neurons, we observed that the expression
levels of several genes were different between the patients. Although
the precise mechanisms behind these differences are currently un-
known, epigenetic mechanisms, such as DNAmethylation and chroma-
tin remodeling, are likely some of themainmechanisms underlying the
differential transcriptional events. Alternatively, although we did not
identify genetic variations in exons using whole exome sequencing, so-
matic de novo mutations might occur in speciﬁc organs, such as the
brain. Rare de novo CNVs should also be considered.Please cite this article as: Nakazawa, T., et al., Differential gene expression
iPS cells from monozygotic twin..., Schizophr. Res. (2016), http://dx.doi.orPrevious genetic association studies have reported that variations in
several genes, such asDRD2, DRD3,HTR2A,HTR3A, NRXN1, KCNH2, GSK3
and BDNF, are candidate drug response predictors for schizophrenia
(Apud et al., 2012; Gressier et al., 2016; Ikeda et al., 2008; Jenkins et
al., 2014; Kohlrausch, 2013; Muller et al., 2013; Souza et al., 2010;
Souza et al., 2008; Sriretnakumar et al., 2015; Zai et al., 2012; Zhang et
al., 2010). These genes converge on the dopamine, serotonin pathways
and the regulation of synaptic functions; however, the current molecu-
lar knowledge of drug response predictors for clozapine is limited. We
observed that the expression levels of homophilic cell adhesion mole-
cules, such as CDH8, DSC3 and protocadherin genes, were different in
the iPS cell-derived neurons derived from each patient (Table 3 and
Fig. 2). The differential expression of homophilic cell adhesion mole-
cules potentially results in alterations in the number and structure of
synapses and dendritemorphology, leading to altered neural circuit for-
mation in the brain. Importantly, taking advantage of recently devel-
oped iPS technology, we can investigate the functional signiﬁcance of
the differential expression of homophilic cell adhesion molecules in pa-
tient-derived live neurons. Additional studies using the monozygotic
twins with schizophrenia are required for validating the present ﬁnd-
ings. However, it is generally very hard to ﬁnd another monozygotic
twin cases with treatment-resistant schizophrenia and discordant re-
sponses to clozapine, because the estimated incidence of a monozygotic
twin of patients with treatment-resistant schizophrenia and discordant
responses to clozapine among schizophrenia patients is only about 0.13
to 0.33 pairs per million patients with schizophrenia (Supplementary
text). The estimation implies that the expected number of monozygotic
twin pairs with treatment-resistant schizophrenia and discordant re-
sponses to clozapine is under about 0.013, even if we investigate schizo-
phrenia patients in the large genetic study (36,989 patients, Ripke et al.,
2014). To the best of our knowledge, our current study is the ﬁrst report
of an extremely rare case of monozygotic twinwith treatment-resistant
schizophrenia and discordant responses to clozapine. In combination
with recently developed iPS cell technology, although there are many
limitations in our current study, our study proposes a new approach
for schizophrenia research.
Instead of monozygotic twin cases, a large number of responder and
non-responder schizophrenia cases who are not monozygotic twin
cases can be useful for validating the expression data; however, with
current technologies, the generation of iPS cells from a large number
of schizophrenia cases would require tremendous cost, time and
manpower.
In the present study, we used iPS-cell-based technology to identify
homophilic cell adhesion molecules as potential candidates for the mo-
lecular basis of clozapine response. These results not only contribute to
the current understanding of the molecular mechanisms of clozapine
action but also provide information for the development of new, effec-
tive treatment strategies.proﬁles in neurons generated from lymphoblastoid B-cell line-derived
g/10.1016/j.schres.2016.10.012
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